Skip to main content

Preferred Sample Type

Procollagen peptide Type 3 (P3NP or PIIINP)

Suitable Specimen Types

  • Serum
2 mL blood (250 uL serum minimum)

Specimen Transport

First class post to Ref Lab.

Sample Processing in Laboratory

Usual to BHH.

Sample Preparation

Centrifuge and separate serum, store serum at -20 deg/celcius if not sent same day.

Transport to Ref Lab only on Monday-Thursday. i.e AVOID the weekend.

Turnaround Time

10 working days

Sample Stability

Store separated serum at -20 ºC if not sent to referral laboratory same day

Procollagen peptide Type 3 (P3NP or PIIINP)

General Information

Collagen is formed initially with pro-peptides at both ends. In the liver the majority of collagen is either type 1 or type 3. The removal of the propeptides promotes development of collagen fibrils. The pro-peptides may either be retained in the matrix or released into the circulation. Fibrosis occuring in the liver results in the deposition of collagen and release of propeptides, predominantly P3NP. Increased P3NP is seen in various liver diseases in which fibrosis/cirrhosis is a major feature e.g. alcoholic liver disease, primary sclerosing cholangitis and also in non-liver diseases where fibrosis is a feature e.g. myelofibrosis, systemic sclerosis etc.

Methotrexate is a successful form of treatment for psoriasis and rheumatoid arthritis (RA). It has, however, been noted that prolonged exposure can result in irreversible hepatic fibrosis the risk of which is idiopathic but associated with cumulative doses of more than 1.5g (usually encountered in psoriasis as lower doses are used in RA). Previously it was advised that a liver biopsy be considered after each cumulative 1.5g methotrexate. In 1996 it was shown that serum P3NP concentrations were predictive of the development of hepatic fibrosis. Continually raised P3NP concentrations were found to be associated with fibrosis in 78-100% of cases, but were only seen in 15-18% of subjects with a normal liver on biopsy. Current guidelines on the use of methotrexate in psoriasis suggest P3NP measurements be carried out annually and three monthly after a raised value.

Patient Preparation

Haemolysed samples are not acceptable.

Serum from red top or SST tubes is suitable for analysis.

Notes

 

 

 

Reference Range

P3NP references ranges in use from 1st April 2014

 Paediatric reference ranges

MALE:

4 – 11 years

11.9 – 29.4  µg/L

12- 16 years

11.9 – 51.8  µg/L

17- 18 years

6.6 – 42.1  µg/L

    

                    

 

 

 

FEMALE:

4 – 10 years

12.7 – 33.5  µg/L

11 – 12 years

13.7 – 52.5  µg/L

13 – 14 years

10.1 – 37.3  µg/L

15 – 18 years

6.6 – 18.8  µg/L

 

 

 

 

 

 

Adult reference ranges:

Green (safe)                      <10.4 µg/L

Amber (warning)             10.4 – 12.9 µg/L

Red (action)                       >12.9 µg/L

 Adult patients on methotrexate:

3.3 – 9.6 µg/L

Source of Reference Range

Provided by Reference Laboratory

Specifications

  • EQA Scheme?: Yes
  • EQA Status: Sample exchange scheme in place